Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways
Identifieur interne : 001D41 ( Main/Corpus ); précédent : 001D40; suivant : 001D42Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways
Auteurs : Rosa M. Sancho ; Bernard M. H. Law ; Kirsten HarveySource :
- Human Molecular Genetics [ 0964-6906 ] ; 2009-10-15.
Abstract
Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.
Url:
DOI: 10.1093/hmg/ddp337
Links to Exploration step
ISTEX:BE217C12B8558C8882B86254096C5720F0FC3EB5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title><author><name sortKey="Sancho, Rosa M" sort="Sancho, Rosa M" uniqKey="Sancho R" first="Rosa M." last="Sancho">Rosa M. Sancho</name><affiliation><mods:affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Law, Bernard M H" sort="Law, Bernard M H" uniqKey="Law B" first="Bernard M. H." last="Law">Bernard M. H. Law</name><affiliation><mods:affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Harvey, Kirsten" sort="Harvey, Kirsten" uniqKey="Harvey K" first="Kirsten" last="Harvey">Kirsten Harvey</name><affiliation><mods:affiliation>E-mail: kirsten.harvey@pharmacy.ac.uk</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BE217C12B8558C8882B86254096C5720F0FC3EB5</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1093/hmg/ddp337</idno><idno type="url">https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001D41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title><author><name sortKey="Sancho, Rosa M" sort="Sancho, Rosa M" uniqKey="Sancho R" first="Rosa M." last="Sancho">Rosa M. Sancho</name><affiliation><mods:affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Law, Bernard M H" sort="Law, Bernard M H" uniqKey="Law B" first="Bernard M. H." last="Law">Bernard M. H. Law</name><affiliation><mods:affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Harvey, Kirsten" sort="Harvey, Kirsten" uniqKey="Harvey K" first="Kirsten" last="Harvey">Kirsten Harvey</name><affiliation><mods:affiliation>E-mail: kirsten.harvey@pharmacy.ac.uk</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Human Molecular Genetics</title><idno type="ISSN">0964-6906</idno><idno type="eISSN">1460-2083</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-10-15">2009-10-15</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">20</biblScope><biblScope unit="page" from="3955">3955</biblScope><biblScope unit="page" to="3968">3968</biblScope></imprint><idno type="ISSN">0964-6906</idno></series><idno type="istex">BE217C12B8558C8882B86254096C5720F0FC3EB5</idno><idno type="DOI">10.1093/hmg/ddp337</idno><idno type="ArticleID">ddp337</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0964-6906</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Rosa M. Sancho</name><affiliations><json:string>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</json:string></affiliations></json:item><json:item><name>Bernard M.H. Law</name><affiliations><json:string>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</json:string></affiliations></json:item><json:item><name>Kirsten Harvey</name><affiliations><json:string>E-mail: kirsten.harvey@pharmacy.ac.uk</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>ARTICLES</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.</abstract><qualityIndicators><score>9</score><pdfVersion>1.5</pdfVersion><pdfPageSize>612 x 797.953 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1800</abstractCharCount><pdfWordCount>7189</pdfWordCount><pdfCharCount>45692</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>253</abstractWordCount></qualityIndicators><title>Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title><genre><json:string>research-article</json:string></genre><host><volume>18</volume><pages><last>3968</last><first>3955</first></pages><issn><json:string>0964-6906</json:string></issn><issue>20</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2083</json:string></eissn><title>Human Molecular Genetics</title></host><categories><wos><json:string>BIOCHEMISTRY & MOLECULAR BIOLOGY</json:string><json:string>GENETICS & HEREDITY</json:string></wos></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1093/hmg/ddp337</json:string></doi><id>BE217C12B8558C8882B86254096C5720F0FC3EB5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>OUP</p></availability><date>2009-07-22</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title><author><persName><forename type="first">Rosa M.</forename><surname>Sancho</surname></persName><affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</affiliation></author><author><persName><forename type="first">Bernard M.H.</forename><surname>Law</surname></persName><affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</affiliation></author><author><persName><forename type="first">Kirsten</forename><surname>Harvey</surname></persName><email>kirsten.harvey@pharmacy.ac.uk</email></author></analytic><monogr><title level="j">Human Molecular Genetics</title><idno type="pISSN">0964-6906</idno><idno type="eISSN">1460-2083</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-10-15"></date><biblScope unit="volume">18</biblScope><biblScope unit="issue">20</biblScope><biblScope unit="page" from="3955">3955</biblScope><biblScope unit="page" to="3968">3968</biblScope></imprint></monogr><idno type="istex">BE217C12B8558C8882B86254096C5720F0FC3EB5</idno><idno type="DOI">10.1093/hmg/ddp337</idno><idno type="ArticleID">ddp337</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009-07-22</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.</p></abstract></profileDesc><revisionDesc><change when="2009-07-22">Created</change><change when="2009-10-15">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-15">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">hmg</journal-id><journal-id journal-id-type="hwp">hmg</journal-id><journal-title>Human Molecular Genetics</journal-title><issn pub-type="ppub">0964-6906</issn><issn pub-type="epub">1460-2083</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/hmg/ddp337</article-id><article-id pub-id-type="publisher-id">ddp337</article-id><article-categories><subj-group subj-group-type="heading"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sancho</surname><given-names>Rosa M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Law</surname><given-names>Bernard M.H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harvey</surname><given-names>Kirsten</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff><addr-line>Department of Pharmacology</addr-line>, <institution>The School of Pharmacy</institution>, <addr-line>29-39 Brunswick Square, London</addr-line>, <country>UK</country></aff><author-notes><corresp id="cor1"><label>*</label>To whom correspondence should be addressed at: <addr-line>Department of Pharmacology</addr-line>, <institution>The School of Pharmacy</institution>, <addr-line>London WC1N 1AX</addr-line>, <country>UK</country>. Tel: <phone>+44 2077535888</phone>; Fax: <fax>+44 2077535902</fax>; Email: <email>kirsten.harvey@pharmacy.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>10</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2009</year></pub-date><volume>18</volume><issue>20</issue><fpage>3955</fpage><lpage>3968</lpage><history><date date-type="received"><day>9</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2009</year></date></history><copyright-statement>© 2009 The Author(s)</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><p>Mutations in <italic>PARK8</italic>, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2–DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2–DVL1-3 interactions were disrupted by the familial <italic>PARK8</italic> mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2–DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by <italic>PARK8</italic> Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2–DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways</title></titleInfo><name type="personal"><namePart type="given">Rosa M.</namePart><namePart type="family">Sancho</namePart><affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bernard M.H.</namePart><namePart type="family">Law</namePart><affiliation>Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kirsten</namePart><namePart type="family">Harvey</namePart><affiliation>E-mail: kirsten.harvey@pharmacy.ac.uk</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2009-10-15</dateIssued><dateCreated encoding="w3cdtf">2009-07-22</dateCreated><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.</abstract><relatedItem type="host"><titleInfo><title>Human Molecular Genetics</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0964-6906</identifier><identifier type="eISSN">1460-2083</identifier><identifier type="PublisherID">hmg</identifier><identifier type="PublisherID-hwp">hmg</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>20</number></detail><extent unit="pages"><start>3955</start><end>3968</end></extent></part></relatedItem><identifier type="istex">BE217C12B8558C8882B86254096C5720F0FC3EB5</identifier><identifier type="DOI">10.1093/hmg/ddp337</identifier><identifier type="ArticleID">ddp337</identifier><accessCondition type="use and reproduction" contentType="copyright">2009 The Author(s)</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/covers/tiff</uri></json:item><json:item><original>true</original><mimetype>text/html</mimetype><extension>html</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/covers/html</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/annexes/gif</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/BE217C12B8558C8882B86254096C5720F0FC3EB5/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">BIOCHEMISTRY & MOLECULAR BIOLOGY</classCode><classCode scheme="WOS">GENETICS & HEREDITY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001D41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BE217C12B8558C8882B86254096C5720F0FC3EB5
|texte= Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways
}}
| This area was generated with Dilib version V0.6.23. |  |